Made in India: 35% of world's fake drugs claim

22 January 2007

One in five drugs sold in India is counterfeit, according to the Associated Chambers of Commerce and Industry of India (Assocham). Worldwide, 35% of all fake drugs originate in India, according to the business organization, in a special report which has been submitted to the Indian federal government.

The Assocham report also estimates that the domestic fake drug market is growing at an astonishing 33% per year, from 30.0 billion rupees ($678.5 million) in 2005 to 40.0 billion rupees last year. The worst offenders in terms of quality control are government hospitals, where about 38% of drugs are fake, nearly double the national average. The Assocham also believes that 60% of fake drugs in India contain no active ingredients, 19% have the wrong substances and 16% include harmful and inappropriate ingredients, such as talcum powder.

The group estimates the damage to the country's economy from all classes of counterfeit goods at 150.0 billion rupees, from an estimated turnover of 300.0 billion rupees. The worst market in terms of counterfeiting is gold and precious materials (India has the world's highest level of private gold holdings), followed by entertainment software piracy and recorded music. However, this calculation assumes the dubious premise that, if the goods were legitimate and taxed, consumers would have the purchasing power to buy the same volume of goods at the higher prices.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight